Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

Exclusion Criteria

• •Malignancy or received treatment for malignancy, other than treated basal cell or squamous cell carcinoma of the skin, within the previous 5 years.
• •Received investigational drug or implantable device in prior 3 months or investigational oligonucleotide in prior 6 months or 5 half-lives of the oligonucleotide, whichever is longer
• •Clinically significant medical condition, unstable psychiatric symptoms, substance abuse, or pregnancy
• •Inability to undergo brain MRI
• •Bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or unsuccessful lumbar puncture